Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCM NASDAQ:MLYS NASDAQ:PVLA NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$16.09-0.2%$16.33$11.51▼$21.50$2.81B0.4555,356 shs68,187 shsMLYSMineralys Therapeutics$38.06-5.9%$25.26$8.24▼$41.09$2.52B0.41.77 million shs958,857 shsPVLAPalvella Therapeutics$65.78+5.0%$51.46$11.17▼$65.80$727.53M-0.13181,002 shs151,211 shsTARSTarsus Pharmaceuticals$65.17+10.9%$52.98$32.57▼$65.97$2.75B0.81716,156 shs1.32 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED0.00%+2.88%+8.42%+1.23%-22.72%MLYSMineralys Therapeutics0.00%-4.83%+14.92%+162.03%+197.34%PVLAPalvella Therapeutics0.00%+10.39%+21.50%+172.72%+6,577,999,900.00%TARSTarsus Pharmaceuticals0.00%+15.78%+13.48%+58.64%+98.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$16.09-0.2%$16.33$11.51▼$21.50$2.81B0.4555,356 shs68,187 shsMLYSMineralys Therapeutics$38.06-5.9%$25.26$8.24▼$41.09$2.52B0.41.77 million shs958,857 shsPVLAPalvella Therapeutics$65.78+5.0%$51.46$11.17▼$65.80$727.53M-0.13181,002 shs151,211 shsTARSTarsus Pharmaceuticals$65.17+10.9%$52.98$32.57▼$65.97$2.75B0.81716,156 shs1.32 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED0.00%+2.88%+8.42%+1.23%-22.72%MLYSMineralys Therapeutics0.00%-4.83%+14.92%+162.03%+197.34%PVLAPalvella Therapeutics0.00%+10.39%+21.50%+172.72%+6,577,999,900.00%TARSTarsus Pharmaceuticals0.00%+15.78%+13.48%+58.64%+98.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$20.8829.74% UpsideMLYSMineralys Therapeutics 2.57Moderate Buy$43.5014.29% UpsidePVLAPalvella Therapeutics 2.92Moderate Buy$69.275.31% UpsideTARSTarsus Pharmaceuticals 2.50Moderate Buy$66.672.30% UpsideCurrent Analyst Ratings BreakdownLatest PVLA, HCM, MLYS, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/2/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $80.009/27/2025HCMHUTCHMEDWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025MLYSMineralys TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PVLAPalvella TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TARSTarsus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/26/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $73.009/25/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $95.009/24/2025PVLAPalvella TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $80.009/22/2025HCMHUTCHMEDMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$18.00 ➝ $13.759/11/2025MLYSMineralys TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $50.009/9/2025HCMHUTCHMEDZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.45$0.29 per share56.02$4.43 per share3.63MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/APVLAPalvella Therapeutics$42.81M16.99N/AN/A$5.58 per share11.79TARSTarsus Pharmaceuticals$182.95M15.04N/AN/A$5.87 per share11.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$37.73MN/A0.0011.02N/AN/AN/AN/AN/AMLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)TARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest PVLA, HCM, MLYS, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.054.654.51MLYSMineralys TherapeuticsN/A15.1215.12PVLAPalvella TherapeuticsN/A7.677.67TARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%MLYSMineralys Therapeutics84.46%PVLAPalvella Therapeutics40.11%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%MLYSMineralys Therapeutics25.56%PVLAPalvella Therapeutics20.50%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableMLYSMineralys Therapeutics2866.29 million49.35 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/ATARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionablePVLA, HCM, MLYS, and TARS HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) Trading 9.6% Higher - Time to Buy?October 3 at 9:43 PM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Should You Buy?September 30, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $332,220.00 in StockSeptember 27, 2025 | insidertrades.comBobak Azamian Sells 6,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) StockSeptember 26, 2025 | marketbeat.comTarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay OffSeptember 26, 2025 | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 25, 2025 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 25, 2025 | marketbeat.com5,600 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Strs OhioSeptember 24, 2025 | marketbeat.comAssenagon Asset Management S.A. Trims Position in Tarsus Pharmaceuticals, Inc. $TARSSeptember 22, 2025 | marketbeat.comWoodline Partners LP Trims Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 15, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 4.1% on Insider SellingSeptember 13, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 27,116 SharesSeptember 12, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and IDEAYA Biosciences (IDYA)September 10, 2025 | theglobeandmail.comAdage Capital Partners GP L.L.C. Acquires New Shares in Tarsus Pharmaceuticals, Inc. $TARSSeptember 7, 2025 | marketbeat.comBaird Financial Group Inc. Decreases Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 7, 2025 | marketbeat.comCormorant Asset Management LP Sells 100,000 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6, 2025 | marketbeat.comCutter Capital Management LP Acquires 92,500 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6, 2025 | marketbeat.comAlly Bridge Group NY LLC Sells 45,212 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 5, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com3 Biotech Catalysts Present Major Opportunity (TARS)...August 25, 2025 | marketbeat.comLyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.August 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVLA, HCM, MLYS, and TARS Company DescriptionsHUTCHMED NASDAQ:HCM$16.09 -0.03 (-0.19%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.97 -0.12 (-0.75%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Mineralys Therapeutics NASDAQ:MLYS$38.06 -2.40 (-5.93%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$39.01 +0.95 (+2.49%) As of 10/3/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Palvella Therapeutics NASDAQ:PVLA$65.78 +3.15 (+5.03%) As of 10/3/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Tarsus Pharmaceuticals NASDAQ:TARS$65.17 +6.40 (+10.89%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$65.70 +0.53 (+0.81%) As of 10/3/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
